PSMA PET Imaging

177Lu-PSMA-617 Theranostics Might Be More Active and Safer than Cabazitaxel 

177Lu-PSMA-617 Theranostics Might Be More Active and Safer than Cabazitaxel 

The trial showed that the LuPSMA treatment delayed prostate cancer progression versus Jevtana, with a comparable benefit observed in radiographic progression-free survival and PSA progression-free survival.

Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer Spread

Data from the phase 2/3 OSPREY 2301 Study has shown that the PSMA-targeted small molecule PET imaging agent (PyL (18F-DCFPyL) designed to better visualize prostate cancer outside of the gland demonstrated high sensitivity and reliably in detecting distant metastatic prostate cancer lesions and also a high specificity in confirming the absence of pelvic lymph nodes.